Trial Profile
An observational study of rivaroxaban to assess various outcomes of cancer patients with blood clots who are treated with an anticoagulant to better understand the treatment of VTE and the prevention of recurrent events in this patient population
Status:
Planning
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2015
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cancer; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms CALLISTO
- 02 Jun 2015 New trial record
- 28 May 2015 This study is a part of CALLISTO clinical research program. This program consists of seven clinical studies and two observational registries.